))
Tackling Drug Resistance in Cancer Treatment – Stefanie Flückiger
Manage episode 443412342 series 3431773
İçerik ETH Zurich tarafından sağlanmıştır. Bölümler, grafikler ve podcast açıklamaları dahil tüm podcast içeriği doğrudan ETH Zurich veya podcast platform ortağı tarafından yüklenir ve sağlanır. Birinin telif hakkıyla korunan çalışmanızı izniniz olmadan kullandığını düşünüyorsanız burada https://tr.player.fm/legal özetlenen süreci takip edebilirsiniz.
Stefanie Flückiger, co-founder and CEO of Tolremo Therapeutics, is transforming cancer treatment with her innovative biotech company. Discover how Tolremo, an ETH spinoff, is tackling non-genetic drug resistance with cutting-edge technology. Hear about Stefanie's unique journey from academia to entrepreneurship, the impact of diversity in driving innovation, and the intriguing science behind cancer cells' resistance to drugs.
This is her story.
Chapters:
(01:06) The Role of Awards and Female Leadership
(03:52) Diversity in Leadership and Innovation
(06:21) The Catalyst for Starting Tolremo
(10:30) Understanding Cancer Cell Resistance
(15:30) From Academia to Biotech: The Journey of Tolremo
(19:47) Stephanie's Academic Background and ETH Experience
(22:34) Closing Thoughts and Personal Insights
Books mentioned:
Why We Sleep by Matthew Walker
Podcast mentioned:
46 bölüm
Paylaş
